ILMN Quote, Financials, Valuation and Earnings

Quest Diagnostics has a net margin of 16.94% compared to Illumina's net margin of 8.47%. Illumina's return on equity of -35.09% beat Quest Diagnostics's return on equity of 12.99%.

Illumina has a consensus price target of $123.72, signalling upside risk potential of 65.45%. On the other hand Quest Diagnostics has an analysts' consensus of $178.80 which suggests that it could grow by 9.03%. Given that Illumina has higher upside potential than Quest Diagnostics, analysts believe Illumina is more attractive than Quest Diagnostics.

Illumina has a beta of 1.376, which suggesting that the stock is 37.551% more volatile than S&P 500. In comparison Quest Diagnostics has a beta of 0.781, suggesting its less volatile than the S&P 500 by 21.91%.

Illumina has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quest Diagnostics offers a yield of 1.86% to investors and pays a quarterly dividend of $0.80 per share. Illumina pays -- of its earnings as a dividend. Quest Diagnostics pays out 38% of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Illumina quarterly revenues are $1.1B, which are smaller than Quest Diagnostics quarterly revenues of $2.6B. Illumina's net income of $187M is lower than Quest Diagnostics's net income of $222M. Notably, Illumina's price-to-earnings ratio is -- while Quest Diagnostics's PE ratio is 21.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina is 2.72x versus 1.88x for Quest Diagnostics. Usually stocks with elevated PS ratios are considered overvalued.

Exact Sciences has a net margin of 16.94% compared to Illumina's net margin of -121.19%. Illumina's return on equity of -35.09% beat Exact Sciences's return on equity of -34.11%.

Illumina has a consensus price target of $123.72, signalling upside risk potential of 65.45%. On the other hand Exact Sciences has an analysts' consensus of $67.33 which suggests that it could grow by 51.48%. Given that Illumina has higher upside potential than Exact Sciences, analysts believe Illumina is more attractive than Exact Sciences.

Illumina has a beta of 1.376, which suggesting that the stock is 37.551% more volatile than S&P 500. In comparison Exact Sciences has a beta of 1.136, suggesting its more volatile than the S&P 500 by 13.608%.

Illumina has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Illumina pays -- of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend.

Illumina quarterly revenues are $1.1B, which are larger than Exact Sciences quarterly revenues of $713.4M. Illumina's net income of $187M is higher than Exact Sciences's net income of -$864.6M. Notably, Illumina's price-to-earnings ratio is -- while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina is 2.72x versus 2.97x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Labcorp Holdings has a net margin of 16.94% compared to Illumina's net margin of 4.31%. Illumina's return on equity of -35.09% beat Labcorp Holdings's return on equity of 9.29%.

Illumina has a consensus price target of $123.72, signalling upside risk potential of 65.45%. On the other hand Labcorp Holdings has an analysts' consensus of $271.12 which suggests that it could grow by 22.42%. Given that Illumina has higher upside potential than Labcorp Holdings, analysts believe Illumina is more attractive than Labcorp Holdings.

Illumina has a beta of 1.376, which suggesting that the stock is 37.551% more volatile than S&P 500. In comparison Labcorp Holdings has a beta of 0.988, suggesting its less volatile than the S&P 500 by 1.19%.

Illumina has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Labcorp Holdings offers a yield of 1.3% to investors and pays a quarterly dividend of $0.72 per share. Illumina pays -- of its earnings as a dividend. Labcorp Holdings pays out 32.59% of its earnings as a dividend. Labcorp Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Illumina quarterly revenues are $1.1B, which are smaller than Labcorp Holdings quarterly revenues of $3.3B. Illumina's net income of $187M is higher than Labcorp Holdings's net income of $143.4M. Notably, Illumina's price-to-earnings ratio is -- while Labcorp Holdings's PE ratio is 25.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina is 2.72x versus 1.44x for Labcorp Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Star Equity Holdings has a net margin of 16.94% compared to Illumina's net margin of -14.37%. Illumina's return on equity of -35.09% beat Star Equity Holdings's return on equity of -17.45%.

Illumina has a consensus price target of $123.72, signalling upside risk potential of 65.45%. On the other hand Star Equity Holdings has an analysts' consensus of $10.00 which suggests that it could grow by 410.73%. Given that Star Equity Holdings has higher upside potential than Illumina, analysts believe Star Equity Holdings is more attractive than Illumina.

Illumina has a beta of 1.376, which suggesting that the stock is 37.551% more volatile than S&P 500. In comparison Star Equity Holdings has a beta of 0.668, suggesting its less volatile than the S&P 500 by 33.205%.

Illumina has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Equity Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Illumina pays -- of its earnings as a dividend. Star Equity Holdings pays out -19.54% of its earnings as a dividend.

Illumina quarterly revenues are $1.1B, which are larger than Star Equity Holdings quarterly revenues of $17.1M. Illumina's net income of $187M is higher than Star Equity Holdings's net income of -$2.5M. Notably, Illumina's price-to-earnings ratio is -- while Star Equity Holdings's PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina is 2.72x versus 0.12x for Star Equity Holdings. Usually stocks with elevated PS ratios are considered overvalued.